Natural killer-dendritic cell cross-talk in cancer immunotherapy. - Wikidata - wikimedia - TriplyDB

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

http://www.wikidata.org/entity/Q36273386

about

IL-15-PI3K-AKT-mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity.Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.Gene expression analysis of ex vivo expanded and freshly isolated NK cells from cancer patients.Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12.Immunotherapy of cancer in 2012.Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands.NK cells influence both innate and adaptive immune responses after mucosal immunization with antigen and mucosal adjuvant.Natural killer cells: from bench to cancer therapy.Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.Killer dendritic cells: mechanisms of action and therapeutic implications for cancer.Immunotherapy for liver tumors: present status and future prospects.Dendritic cell-based therapeutic cancer vaccines: what we have and what we need.Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4 Acupuncture as anticancer treatment?Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy.Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.Role of tyrosine kinase inhibitors in tumor immunology.Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity.Role of TNF superfamily ligands in innate immunity.Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas.Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.Phenotypic plasticity of MDSC in cancers.Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.Immune activation by combination human lymphokine-activated killer and dendritic cell therapy ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.The Critical Role of IL-15-PI3K-mTOR Pathway in Natural Killer Cell Effector Functions.Salmonella typhimurium stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model.CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer.Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML Dysfunctions in the Mature Dendritic Cells Are Associated with the Presence of Metastases of Colorectal Cancer in the Surrounding Lymph Nodes.Prevention of Mammary Tumor Development through Neuroimmunomodulation in the Spleen and Lymph Nodes of Old Female Sprague-Dawley Rats by L-Deprenyl.OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity.Ex vivo expansion of human peripheral blood natural killer cells and cytotoxic T lymphocytes from lung cancer patients.Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets.

P2860

Q26800159-BB6C997B-E46F-41F3-88BC-62B0A1335945 Q28508164-10327690-C450-446F-9257-8EFAD972FEFC Q34022257-CF4B91F1-3942-417C-8108-2C022C7DF63E Q34023502-531AC54B-AEF9-456E-B45D-A79544F18945 Q34194706-960FD2D6-7189-4846-9ABE-A19FA05B84A2 Q34985704-ECF43DAF-D905-4C28-8E19-6538B1329D5A Q35809223-ED8D288A-2656-4918-9620-CBA3A0D9DAD8 Q36243536-13B5D6B5-F3F4-4929-A349-CC3EE2C75203 Q36388514-ACFA9387-AA3F-494F-920A-D0CD74E2CDCC Q36455293-3A45C54A-9600-462A-8DAE-0ED1C549EB1F Q36600223-FD74E905-EA7F-4B52-8587-D06BD6E148AC Q36810264-2DFECF1E-9F1C-4F41-9A64-723CF35B8B90 Q36975755-946BF56A-E20A-40DD-9072-B6117C3E86E8 Q37144014-72C1E2A7-83B7-40A8-9761-244DC34D1944 Q37448957-84807F02-ECCB-4D1C-ABC3-D78F48CC0DC1 Q37513871-8C4C32B7-0999-4472-83EC-746251164E0E Q37657657-51554368-B74F-47E2-B021-D741202ECAB0 Q37729135-15706F16-D9E8-42BA-9F91-25A26E087A76 Q37735454-BFB34A78-1B6C-4147-B37C-06C1A32141A4 Q37822748-F0866D82-D893-4B2F-B614-3E8B8FBA45A2 Q37885284-7A7B4A8E-0AB8-4C42-8CEB-2ED2137A7E33 Q37895956-0FA02CC4-322C-4BD3-860C-CC12992B1DE2 Q37895960-7895EEF9-B9E2-4305-952E-07AA94F39198 Q37952245-4B8B17C7-7A65-406A-8CC1-0DBECD43B590 Q38031222-6C7F6A70-A548-4000-9952-BC5EF61B4F9A Q38047054-F774F123-B6D0-4326-B21B-879981DAD43A Q38081981-A9464337-0C03-45C8-953A-BA7705C45943 Q38258842-C18FCD6B-D410-4DE8-99B9-31EB2ADD58CC Q38370628-14229CD5-2968-4759-AB12-D5B9BC88F7A2 Q38814097-8F98DC37-5795-484B-A6EF-F8975E962193 Q39102232-8279E561-042F-4288-AF21-F0D4730F6C04 Q40141190-9E3D6CD2-94FA-4D09-B88D-F2253804D882 Q41067857-B813ABB7-3B2E-4AC3-810B-4808FD50D5DB Q41520681-1D787CE7-30B0-421A-BFE3-DEED19AFA897 Q42106581-4F1CE050-6A11-462F-8361-6A3A1326725A Q43093248-FD871379-78A7-41D4-810E-492C0B703287 Q45175593-56359A04-E416-476F-837F-719EA818DEED Q45967667-1EA738CE-E906-42D9-A7DF-C3B9EC99DD58 Q55211345-6A3C90D1-A0E6-44D0-A402-9C6BCB35E63B Q55280499-5EA7C966-4F8A-42F4-98A8-A3DFACDBA346

P2860

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

http://www.wikidata.org/entity/Q36273386

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

@ast

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

@en

type

label

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

@ast

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

@en

prefLabel

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

@ast

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

@en

P1433

Q36273386-D5A7DA2C-3A49-4694-947B-7DC692A50DEA

P1476

Q36273386-915D9C56-B4F1-4F59-B711-EE87F50810D6

P2093

Q36273386-179E71C7-3C5F-49C8-9E64-5D3D46E7D443

Q36273386-418C7605-5412-4F64-AB25-1A92DFBC00F0

Q36273386-519121B8-A4BA-40B8-A265-56AE4E7A6C7A

Q36273386-7EE23351-6998-4F64-AA94-4B43CEB8BCBB

Q36273386-89C6A99D-F5B8-4708-893D-5D14E59E6C38

Q36273386-96A9A905-0D2A-4C36-92E8-C1570E6A8222

Q36273386-CF9FE209-D22A-47EA-B2BF-8B240406AEF1

Q36273386-D713C68E-9021-4FB8-8E59-17DDA1A00145

Q36273386-FF821766-7E02-4E23-B8CF-78F6A9BD78C6

P304

Q36273386-B068A224-FD4D-4CB5-8C3B-6BBA5B916F8B

P31

Q36273386-354945B9-8198-4BC5-9EE2-3A2F3C706BA5

P356

Q36273386-9A6B910A-F691-48DB-AA4A-134A509C1D3E

P407

Q36273386-9E4AAC9A-6C49-4CC7-B95E-9F82E71F8122

P433

Q36273386-C0491A57-197F-428A-BABA-37D10C15E2CA

P478

Q36273386-ABDE90DB-91C5-48AB-A888-CBF33F8BD509

P577

Q36273386-42D93509-6787-4F82-8660-9AC6AFD6B548

P698

Q36273386-1340C640-FCCF-47A7-BA2F-C32EB9F35FBB

P921

Q36273386-1AF990CF-3127-44D8-BAD7-3B6630F7918B

P356

14712598.5.10.1303

P1433

Expert Opinion on Biological Therapy

P1476

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

@en

P2093

Adam Giermasz

http://www.w3.org/2001/XMLSchema#string

David L Bartlett

http://www.w3.org/2001/XMLSchema#string

Herbert J Zeh

http://www.w3.org/2001/XMLSchema#string

John M Kirkwood

http://www.w3.org/2001/XMLSchema#string

Michael T Lotze

http://www.w3.org/2001/XMLSchema#string

Pawel Kalinski

http://www.w3.org/2001/XMLSchema#string

Per Basse

http://www.w3.org/2001/XMLSchema#string

Robbie B Mailliard

http://www.w3.org/2001/XMLSchema#string

Ronald B Herberman

http://www.w3.org/2001/XMLSchema#string

P304

1303-1315

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.5.10.1303

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16197336

http://www.w3.org/2001/XMLSchema#string

P921